TriangleExtracorporeal Photopheresis (NCT04930653)
Extracorporeal Photopheresis trial for Folliculotropic Mycosis Fungoides (NCT04930653). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with mycosis fungoides or Sézary syndrome, stage IB or higher, who have not received mogamulizumab. The safety lead-in has stricter stage criteria.
The idea: intravenous mogamulizumab targets CCR4 on T cells. From cycle two, photopheresis removes blood, exposes separated white cells to ultraviolet light, and returns them. Researchers test the combination’s safety and lymphoma response. Treatment lasts six 28-day cycles; responders may receive six more.
This phase 2 study plans 34 patients. Christiane Querfeld leads at City of Hope in Duarte, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.